These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31072237)

  • 1. Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma.
    Hu JL; Luo WJ; Wang H
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819846636. PubMed ID: 31072237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
    He X; Zhang S; Chen J; Li D
    Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
    Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
    Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
    Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
    Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype.
    Wang HY; Li JY; Liu X; Yan XY; Wang W; Wu F; Liang TY; Yang F; Hu HM; Mao HX; Liu YW; Zhang SZ
    Oncotarget; 2016 Nov; 7(46):74895-74903. PubMed ID: 27713134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
    Chai Y; Wang C; Liu W; Fan Y; Zhang Y
    J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
    Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
    Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.
    Thomas AA; Fisher JL; Rahme GJ; Hampton TH; Baron U; Olek S; Schwachula T; Rhodes CH; Gui J; Tafe LJ; Tsongalis GJ; Lefferts JA; Wishart H; Kleen J; Miller M; Whipple CA; de Abreu FB; Ernstoff MS; Fadul CE
    Neuro Oncol; 2015 Jun; 17(6):801-9. PubMed ID: 25618892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas.
    Yang F; Yang P; Zhang C; Wang Y; Zhang W; Hu H; Wang Z; Qiu X; Jiang T
    Oncotarget; 2017 Jun; 8(26):42974-42982. PubMed ID: 28496000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High EMP3 expression might independently predict poor overall survival in glioblastoma and its expression is related to DNA methylation.
    Yue H; Xu Q; Xie S
    Medicine (Baltimore); 2018 Jan; 97(1):e9538. PubMed ID: 29505529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.